Skip to content
sellWeak cluster of 410b5-1 plan

Todd Watanabe sold $64k of ARQT

See Remarks at Arcutis Biotherapeutics, Inc.. 3,671 shares at an average of $17.55, traded Mar 24, 2025, filed Mar 26, 2025.

Warning score
18
Value
$64k
3,671 shares
Holdings after
925,243
-0% from before
From 52-week low
+108%
low $8.31, close $17.29
From 52-week high
0%
high $17.29, as of Mar 24, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $64k at market
    +8
  • Share of holdings sold
    Sold 0.4% of holdings
    0
  • Cluster
    4 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ARQTOct 9, 2026 · close 26.58
Since filing Mar 26, 2025: +61.4%SPY +39.2% · excess +22.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001787306-25-000050, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 24, 2025SOpen-market sale
Common Stock10b5-1
-1,500$17.52$26k927,414Mar 26, 2025
Mar 25, 2025SOpen-market sale
Common Stock10b5-1
-2,171$17.56$38k925,243Mar 26, 2025

Related signals

Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
12Weak
ARQTsell 210b5-1
Arcutis Biotherapeutics, Inc.
Masaru Matsuda
See Remarks
$92k
3,674 shares
-3%
3Weak
ARQTsell 210b5-1
Arcutis Biotherapeutics, Inc.
Howard G. Welgus
director
$114k
4,730 shares
-12%
16Weak
ARQTsell 210b5-1
Arcutis Biotherapeutics, Inc.
Masaru Matsuda
See Remarks
$250k
9,989 shares
-8%
22Weak
ARQTsell 310b5-1
Arcutis Biotherapeutics, Inc.
Todd Watanabe
See Remarks
$178k
10,129 shares
-1%
34Weak
ARQTsell 310b5-1
Arcutis Biotherapeutics, Inc.
Masaru Matsuda
See Remarks
$584k
36,130 shares
-18%
6Weak
ARQTsell 410b5-1
Arcutis Biotherapeutics, Inc.
Howard G. Welgus
director
$156k
10,000 shares
-9%
11Weak
ARQTsell 210b5-1
Arcutis Biotherapeutics, Inc.
Patrick Burnett
See Remarks
$66k
4,188 shares
-4%
17Weak
ARQTsell 510b5-1
Arcutis Biotherapeutics, Inc.
Patrick Burnett
See Remarks
$54k
3,847 shares
-3%
6Weak
ARQTsell 510b5-1
Arcutis Biotherapeutics, Inc.
Howard G. Welgus
director
$143k
10,000 shares
-9%
19Weak
ARQTsell 510b5-1
Arcutis Biotherapeutics, Inc.
Masaru Matsuda
See Remarks
$91k
6,330 shares
-3%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Todd Watanabe sold $64k of ARQT | InsiderTell